Key Dates

Related Announcements

• August 3, 2022 - Notice of Special Interest (NOSI): HEAL Initiative: Opioid Use Disorder Care Pathways for Individuals with Histories of Exposure to Violence. See Notice NOT-DA-23-007

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this notice is to announce the participation of the National Institute on Drug Abuse (NIDA), effective immediately, in a joint initiative, the Incorporating Human Behavior in Epidemiological Models (IHBEM) Program, in collaboration with the National Science Foundation (NSF).

The IHBEM announcement is released under NSF-23-546. The purpose of the IHBEM activity is to support interdisciplinary collaborations that integrate research on behavioral and/or social processes in mathematical epidemiological models. Projects supported under this activity should be collaborative in nature and have coordinated interaction of two or more PIs/co-PIs, with balanced participation from the mathematical sciences and the social, behavioral, or economic sciences. Additional participants from other disciplines, especially the biological sciences, are also welcome.

NIDA is specifically interested in applications that support scientific research on substance use and its health and social consequences across the spectrum, from occasional use to problematic use and substance use disorders (SUDs), that integrates social, behavioral, or economic processes to respond to the public health crisis such as drug overdose, HIV, and HCV. Some examples of areas of interest include:

• Using technology and advanced statistical methods to inform our understanding of both social, behavioral and neurobiological components of substance use that are strongly influenced by diverse environmental and social factors in the context of responding to public health crisis such as drug overdose, HIV, and HCV.
• The development and validation of technologies, analytics, and models to help individuals gather, manage, and use data and information related to drug use and their personal health in the context of responding to public health crisis such as drug overdose, HIV, and HCV.
• Methods and algorithms for aggregation of data including, but not limited to, electronic health records (EHRs), laboratory generated data, environmental, and/or behavioral data.
• Diagnostic/monitoring tools and technology platforms to optimize drug use interventions and delivery, in the context of responding to public health crisis such as drug overdose, HIV, and HCV.

NIH/NIDA Additional Eligibility Information

• Clinical trials are not allowed. The NIH will only consider applications that do not propose clinical trials. Individuals who are considering submitting a proposal in response to this solicitation should review https://grants.nih.gov/ct-decision/ in determining whether the project meets the NIH definition of a Clinical Trial.
• NIH/NIDA and its staff are ineligible to be involved in any proposals submitted to this funding opportunity, including as unfunded collaborators, via letters of collaboration or support, or via any other means.

Application Preparation and Submission Instructions

Proposals submitted in response to this program solicitation should be prepared and submitted in accordance with the general guidelines contained in the NSF Proposal & Award Policies & Procedures Guide (PAPPG). The complete text of the PAPPG is available electronically on the NSF website at: https://www.nsf.gov/publications/pub_summ.jsp?ods_key=pappg. Paper copies of the PAPPG may be obtained from the NSF Publications Clearinghouse, telephone (703) 292-8134 or by e-mail [email protected]. Proposers are reminded to identify this program solicitation number in the program solicitation block on the NSF Cover Sheet for Proposal to the National Science Foundation. Compliance with this requirement is critical to determining the relevant proposal processing guidelines. Failure to submit this information may delay processing.

Budgetary Information

Under this solicitation, proposals may be submitted for an award duration of 3-4 years and with total budget of up to $1,000,000. The budget must be commensurate with the project and thoroughly justified in the proposal. The IHBEM Program expects to fund approximately 10-15 awards per year, depending on the quality of submissions and the availability of funds.

Inclusion of voluntary committed cost sharing is prohibited.

NIH Process

Proposals selected for funding consideration by NIH will be invited to submit reformatted applications to the Division of Receipt and Referral (DRR) within NIH's Center for Scientific Review (CSR). Following the initial peer review, recommended applications that have been resubmitted to the NIH are required to go to second level review by the National Advisory Council on Drug Abuse (NACDA) . PD/PIs invited to submit to NIH will receive further information on submission procedures from NIH. An applicant will not be allowed to increase the proposed budget or change the scientific content of the proposal in their submission to the NIH. For information purposes, NIH PD/PIs may wish to consult the OER website which provides excellent general information about all aspects of NIH grantsmanship, including competitive renewals (https://grants.nih.gov/grants/grants_process.htm).

The following will be considered in making funding decisions:

• Scientific and technical merits of the proposed project as determined by scientific peer review.
• Availability of funds.
• Relevance of the proposed project to program priorities.

Subsequent award processing and grant administration procedures will be in accordance with NIH policies and procedures.

Information about all aspects of NIH grantsmanship, including competitive renewals (https://grants.nih.gov/grants/grants_process.htm).

Inquiries

Please direct all inquiries to:

Inquiries are encouraged and NIH Scientific/Research contacts are listed below. Please see the NSF IHBEM website for names and contact information of participating NSF Directorates.

Susan N. Wright, PhD
National Institute on Drug Abuse (NIDA), Division of Neuroscience and Behavior (DNB)
Telephone: (301) 402-6683
Email: [email protected]

Janet Kuramoto-Crawford, PhD
National Institute on Drug Abuse (NIDA), Division of Epidemiology, Services and Prevention Research (DESPR)
Telephone: (301) 443-8856
Email: [email protected]